Search results
Short Interest in Novavax, Inc. (NASDAQ:NVAX) Drops By 15.6%
ETF DAILY NEWS· 7 days agoNovavax, Inc. (NASDAQ:NVAX – Get Free Report) was the recipient of a significant decline in short interest during the month of May. As of May 31st, there was short interest ...
A Synergy Of Excellence: Novavax-Mabion Partnership During Unprecedented Times Amid The Covid-19...
BioresearchOnline· 2 days agoNovavax's COVID-19 vaccine, Nuvaxovid, was developed in record time with the support of Mabion, a...
Novavax’s South African Phase IIb COVID-19 vaccine trial likely to reveal results within next...
Pharmaceutical Technology via Yahoo Finance· 4 days agoSouth Africa’s existing regulatory, consent and ethics frameworks around HIV vaccine trial investigations helped with regards to quick initiation and straightforward progress of COVID-19 vaccine trials in the country, the source said.
Jim Cramer Says He's 'Going To Have To Wait' On SoFi, But Recommends This 'Great Little Industrial...
Benzinga· 5 days agoOn CNBC's “Mad Money Lightning Round,” Jim Cramer said he still can't recommend Twilio TWLO. On June...
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
InvestorPlace· 4 days agoIt was not long ago that Novavax (NASDAQ:NVAX) was among the stocks with high short interest. In the...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Novavax applies for FDA nod for its updated COVID vaccine
Center for Infectious Disease Research and Policy· 4 days agoThe company said it will have the vaccine ready to distribute in mid July as prefilled syringes, pending approval and recommendations.
COVID vaccine companies told to focus on KP.2 variant for fall shots, per FDA announcement
Fox News via Yahoo News· 7 days agoThe U.S. Food and Drug Administration (FDA) has recommended that COVID vaccine manufacturers update...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 1 day agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Why 93% Of This Biotech's Value Just Went Up In Smoke
Investor's Business Daily· 4 days agoWedbush analyst Laura Chico slashed her price target on Aerovate stock to 3 from 41, calling the...